asco

Oncology

Post-ASCO 2025, Eric Matthews, chief business officer at Caris Life Sciences, discusses advancing the frontier of cancer diagnostics and treatment.

Oncology

Dr Corina Dutcus, senior vice president and oncology global clinical development lead at Eisai, discusses the data Eisai presented at ASCO 2025.

Oncology

Oncology

At ASCO25, AstraZeneca presented late-breaking data from the DESTINY-Breast09 Phase III trial. Alison Dziarmaga discussed the data with pharmaphorum.

Digital

In a post-ASCO 2025 conversation, pharmaphorum web editor Nicole Raleigh spoke with Dr Pamela Tenaerts, chief medical officer at Medable.

Oncology

Mark Wildgust, VP of global medical affairs, oncology, at Johnson & Johnson Innovative Medicine, discusses J&J’s ambition to get in front of cancer.